NCT07310771尚未招募2 期
A Single-Arm Phase II Study of Sintilimab Plus Nimotuzumab and Chemotherapy Followed by Definitive Chemoradiotherapy With Nimotuzumab for Locally Advanced Head and Neck Squamous Cell Carcinoma
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 23
- 主要终点
- Larynx-preservation rate at 3 months post-radiotherapy
研究概览
简要总结
Although multiple immune-checkpoint inhibitors (ICIs) have demonstrated efficacy in recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M-SCCHN), outcomes in the locally advanced (LA-SCCHN) setting remain suboptimal, and treatment continues to pose a major therapeutic challenge. Incremental improvements in efficacy are still required, necessitating the development of more effective regimens. Whether combining an ICI with chemotherapy and nimotuzumab can confer additional clinical benefit in LA-SCCHN remains to be determined. Against this backdrop, we designed a single-arm, phase II, single-centre clinical trial to evaluate the efficacy and safety of sintilimab plus chemotherapy and nimotuzumab for patients with LA-SCCHN.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of written informed consent, with full understanding of and agreement to comply with study requirements and the visit schedule.
- •Age 18-75 years (inclusive) at the time of informed consent; either sex.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Histologically or cytologically confirmed stage III-IVB squamous cell carcinoma of the head and neck as assessed by the investigator.
- •Documented EGFR-positive tumor.
- •No prior systemic therapy for head and neck squamous cell carcinoma.
- •At least one measurable lesion per RECIST v1.
- •Estimated life expectancy ≥ 12 weeks.
- •Adequate bone-marrow and organ function.
排除标准
- •Known hypersensitivity to any component of PD(L)-1 inhibitors, paclitaxel, or cisplatin.
- •Prior or concurrent malignancy (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, or papillary thyroid carcinoma disease-free for >5 years).
- •Uncontrolled cardiac symptoms or clinically significant cardiac disease.
- •Previous therapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, or receipt of therapeutic cancer vaccines or live vaccines within 4 weeks before first study-dose administration.
- •Failure to recover to ≤ Grade 1 (per CTCAE) from prior anti-tumour therapy-except alopecia or residual neurotoxicity related to prior platinum-before first study dose.
- •Severe infection (> CTCAE Grade 2) within 4 weeks before first study dose.
- •Active autoimmune disease or documented autoimmune-disease history requiring systemic therapy.
- •History of immunodeficiency, including positive HIV test, congenital or acquired immunodeficiency syndromes, or prior solid-organ or allogeneic bone-marrow transplantation.
- •History of interstitial lung disease or non-infectious pneumonitis.
- •Evidence of active tuberculosis infection on history or CT imaging.
- •Active hepatitis B (HBV DNA ≥ 500 IU/mL or ≥ 2,500 copies/mL).
- •History of substance abuse, alcohol abuse, or drug addiction.
- •Pregnant or lactating women.
- •Any condition that, in the investigator's opinion, could necessitate premature withdrawal from the study.
研究组 & 干预措施
Sintilimab combined with chemotherapy and nimotuzumab for patients with LA-SCCHN
Experimental
干预措施: Sintilimab combined with chemotherapy and nimotuzumab (Drug)
结局指标
主要结局
Larynx-preservation rate at 3 months post-radiotherapy
时间窗: 3 months
次要结局
- objective response rate(24 months)
- One-year progression-free survival (PFS) rates(12 months)
- Two-year progression-free survival (PFS) rates(24 months)
- One-year loco-regional relapse-free survival (LRFS) rates.(12 months)
- two-year loco-regional relapse-free survival (LRFS) rates.(24 months)
- One- year distant-metastasis-free survival (DMFS) rates.(12 months)
- two-year distant-metastasis-free survival (DMFS) rates(24 months)
- One-year larynx-preservation rates(12 months)
- AE/SAE(42 months)
研究者
相似试验
进行中（未招募）
3 期
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical StudyEsophageal CancerNCT07306663Jiangsu Cancer Institute & Hospital242
招募中
2 期
Immunoprevention for High-risk Lung LesionsNCT07284485Robert Samstein59
招募中
3 期
Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)2023-506291-28-00Centre Leon Berard124
招募中
2 期
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (CERPASS)2024-512652-38-00Replimune Group Inc.143
已完成
2 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer2024-516004-42-01Bristol Myers Squibb International Corporation143